Microbial therapy for MASLD trial
Part of Hormones & metabolism clinical trials.
This trial tests a new microbial therapy for MASLD, a type of fatty liver disease. It aims to improve liver health by targeting gut microbes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your FibroScan test must show a CAP score of 260 db/m or higher.
- You cannot be pregnant or breastfeeding.
- No probiotics, prebiotics, yogurt, or Yakult in the 14 days before screening.
- No antibiotics or antifungal pills in the past 30 days.
- No use of GLP-1 receptor agonist medicines (like Ozempic) in the past 6 months.
- You must not have taken certain other medicines (like steroids, statins, metformin, etc.) in the past 14 days unless you've been on them for over 6 months at a steady dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether aspirin can help people with MASLD, a type of fatty liver disease linked to conditions like diabetes and obesity. It aims to see if aspirin can improve liver health without causing harm.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
This study is testing whether an MRI can help doctors see liver scarring (fibrosis) in people with MASLD, a type of fatty liver disease. It is for patients who already need a liver biopsy as part of their care, to compare the MRI results with the biopsy.
This trial tests whether a probiotic mixture can improve liver health in people with moderate fatty liver disease (MASLD). It looks at how the probiotic affects liver fat, inflammation, and metabolism.
This trial tests whether a special mix of probiotics can help improve liver health in people with fatty liver disease related to metabolism. It measures changes in liver enzymes, fat, and stiffness over time.
Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.